In this article, we assess histologically validated quantitative parameters on 18F-piflufolastat (18F-DCFPyL) prostate-specific membrane antigen (PSMA) PET and identify thresholds for differentiating ...

Tertiary lymphoid structures (TLS) have emerged as critical immune niches within the tumor microenvironment across various cancers. However, their structural organization and functional roles in ...

Andrea Apolo presents a bone metastasis subanalysis from CheckMate-9ER, encompassing roughly 650 patients with metastatic clear cell renal cell carcinoma, around 25% of whom had bone metastases ...

Andrea Apolo discusses three nectin-4 ADC trials. EV-302's 3.5-year follow-up showed median overall survival of 33.6 months with enfortumab vedotin plus pembrolizumab, and 30% of patients achieved ...

The advent of prostate-specific membrane antigen (PSMA)-targeted radioligand therapies (PSMA-RLT), particularly those based on Lutetium-177 ([177Lu]Lu-PSMA), has substantially reshaped the therapeutic ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Michael Ong describes the TRIPLE-SWITCH trial design, a phase 3 study randomizing patients with metastatic hormone-sensitive prostate cancer and PSA of 0.2 or above at six to twelve months of ADT plus ...

Despite Bacillus Calmette-Guerin (BCG) remaining the standard of care for high-risk non-muscle-invasive bladder cancer (HR-NMIBC), novel combination strategies are being actively investigated.

The management of metastatic hormone-sensitive prostate cancer (mHSPC) has rapidly evolved into a complex landscape of doublet and triplet combination strategies. While treatment intensification was ...

The publication of our phase 3 trial of aglatimagene besadenovec in The Lancet Oncology represents an important milestone in the treatment of localized prostate cancer. While the primary publication ...

Prostate cancer (PCa) has been identified as the most prevalent form of cancer among males and the third leading cause of death from cancer in the European male population. Early-stage PCa can be ...

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and ...